| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 24, 2024 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec | – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –
– Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevu... |
| May 6, 2024 | Immunic to Participate in Investor and Scientific Conferences in May | NEW YORK, May 6, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced pa... |
| May 1, 2024 | Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update | – Webcast to be Held at 8:00 am ET on May 8, 2024 –
NEW YORK, May 1, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic infl... |
| Apr 30, 2024 | Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation | – 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks –
– Improvements in Serum Neurofilament Light Chain Consistent with Recently ... |
| Oct 10, 2022 | USD 60 million equity for Immunic | The company Immunic, focused on the treatment of chronic inflammatory and autoimmune diseases, has announced the closing of a securities purchase agreement with select accredited investors and certain existing investors. Immunic, which has ... |
| Aug 17, 2022 | Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium | Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium |
| Jul 7, 2022 | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén | Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén |
| May 5, 2022 | Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease | Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease |
| Feb 24, 2022 | Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity | – Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection – |
| Feb 3, 2022 | Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor | DGAP-News: Immunic, Inc. / Key word(s): Patent
Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
02.02.2022 / 22:01
The is... |
| Feb 3, 2022 | Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor | NEW YORK, Feb. 2, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| Dec 14, 2021 | Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor | – Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects – |
| Dec 10, 2021 | Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer | NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| Dec 10, 2021 | Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer | DGAP-News: Immunic, Inc. / Key word(s): Study
Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer
09.12.2021 / 22:01
The issuer is solely responsible for... |
| Dec 10, 2021 | Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer | NEW YORK, Dec. 9, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, to... |
| Nov 22, 2021 | Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis | NEW YORK, Nov. 18, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| Nov 19, 2021 | Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis | DGAP-News: Immunic, Inc. / Key word(s): Study
Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis
18.11.2021 / 22:01
The issuer is solely respon... |
| Nov 19, 2021 | Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis | NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, ... |
| Nov 4, 2021 | Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity | NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| Nov 4, 2021 | Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity | NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| Nov 4, 2021 | Immunic, Inc. Reports Third Quarter 2021 Financial Results and Highlights Recent Activity | – Fully Enrolled Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis – |
| Oct 28, 2021 | Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis | NEW YORK, Oct. 28, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today an... |
| Oct 28, 2021 | Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis | |
| Oct 28, 2021 | Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis | DGAP-News: Immunic, Inc. / Key word(s): Study
Immunic, Inc. Announces Completion of Enrollment of its Phase 2 CALDOSE-1 Trial of IMU-838 in Moderate-to-Severe Ulcerative Colitis
28.10.2021 / 12:30
The issuer is solely responsible for the co... |
| Oct 27, 2021 | Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935 | DGAP-News: Immunic, Inc. / Key word(s): Study
Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935
27.10.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, In... |
| Oct 27, 2021 | Immunic, Inc. Announces First Psoriasis Patient Enrolled in Ongoing Phase 1 Trial of IMU-935 | NEW YORK, Oct. 27, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, ... |
| Oct 15, 2021 | Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer | NEW YORK, Oct. 14, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, a... |
| Oct 1, 2021 | Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis | NEW YORK, Sept. 30, 2021 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, ... |
| Sep 22, 2021 | Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19 | Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19 |
| Aug 6, 2021 | Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity | NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| Aug 6, 2021 | Immunic, Inc. : Reports Second Quarter 2021 Financial Results and Highlights Recent Activity | NEW YORK, Aug. 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, t... |
| Jul 20, 2021 | Immunic, Inc. Announces Closing of $45.0 Million Public Offering | Immunic, Inc. Announces Closing of $45.0 Million Public Offering |
| Jul 19, 2021 | Immunic, Inc. : Announces Closing of $45.0 Million Public Offering | NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory... |
| Jul 19, 2021 | Immunic, Inc. Announces Closing of $45.0 Million Public Offering | |
| Jul 19, 2021 | Immunic, Inc. Announces Closing of $45.0 Million Public Offering | NEW YORK, July 19, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory... |
| Jul 15, 2021 | Immunic, Inc. : Announces Pricing of $45 Million Public Offering of Common Stock | NEW YORK, July 15, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory... |
| Jul 15, 2021 | Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock | |
| Jul 14, 2021 | Immunic, Inc. : Announces Proposed Public Offering of Common Stock | NEW YORK, July 14, 2021 /PRNewswire/ -- Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory... |
| Jul 12, 2021 | Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist | NEW YORK, July 12, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, ... |
| Jul 1, 2021 | Immunic : Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis | DGAP-News: Immunic, Inc. / Key word(s): Study
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
01.07.2021 / ... |
| Jul 1, 2021 | Immunic, Inc. : Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis | NEW YORK, July 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today ann... |
| Jun 1, 2021 | Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel | |
| Jun 1, 2021 | IMMUNIC, INC.
Immunic, Inc. : Announces Appointment of Inderpal Singh as General Counsel | NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, ann... |
| Jun 1, 2021 | Immunic : Announces Appointment of Inderpal Singh as General Counsel | DGAP-News: Immunic, Inc. / Key word(s): Personnel
Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
01.06.2021 / 12:30
The issuer is solely responsible for the content of this announcement.
Immunic, Inc. Announces App... |
| May 6, 2021 | Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity | NEW YORK, May 6, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today anno... |
| Apr 15, 2021 | Immunic : Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection | DGAP-News: Immunic, Inc. / Key word(s): Study results
Immunic, Inc. Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection
15.04.202... |
| Apr 15, 2021 | IMMUNIC, INC.
Immunic, Inc. : Announces EMPhASIS Interim Analysis of 10 mg Cohort Confirms IMU-838's Dose Response in Relapsing-Remitting Multiple Sclerosis and Supports Phase 3 Dose Selection | NEW YORK, April 15, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today a... |
| Mar 31, 2021 | Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838 | NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflam... |
| Feb 26, 2021 | Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity | NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, to... |
| Feb 18, 2021 | Immunic : Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis | DGAP-News: Immunic, Inc. / Key word(s): Study results
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis
18.02.2021 / 12:30
The iss... |
| Feb 18, 2021 | Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis | NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, to... |
| Feb 17, 2021 | Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial | NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, to... |
| Feb 11, 2021 | Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25 | NEW YORK, Feb. 11, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, to... |
| Sep 28, 2020 | Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19 | NEW YORK, September 28, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today annou... |
| Aug 10, 2020 | Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters’ Option to Purchase Additional Shares | NEW YORK, August 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the ... |
| Sep 28, 2016 | Immunic wraps up €17.5M Series A, buys immunology programs from 4SC | LSP and LifeCare Partners have co-led a €17.5 million ($19.6 million) Series A investment in Immunic, a 5-month-old immunology biotech. The cash has enabled Immunic to buy cytokine inhibitor and Crohn’s disease programs from 4SC (FRA:VSC), ... |
| Immunic successfully closes 17.5 million Euro Series A financing round | Immunic AG (Immunic), a recently formed private start-up biotech company in Planegg-Martinsried near Munich, Germany, today announced that it has closed its Series A financing round totaling EUR 17.5 million of preferred stock financing. Th... |